



Sociedad Española
de Reumatología -
Colegio Mexicano
de Reumatología

Reumatología Clínica

www.reumatologiaclinica.org



Brief Report

Esophageal symptoms and their lack of association with high-resolution manometry in systemic sclerosis patients

Ana Cecilia Arana-Guajardo^a, Gustavo Barrera-Torres^b, Miguel Ángel Villarreal-Alarcón^a, David Vega-Morales^{a,*}, Jorge Antonio Esquivel-Valerio^a

^a Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico

^b Universidad Autónoma de Nuevo León, Servicio de Gastroenterología, Departamento de Medicina Interna, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico

ARTICLE INFO

Article history:

Received 25 June 2017

Accepted 15 September 2017

Keywords:

Systemic sclerosis

Esophageal disease

Comorbidity

High resolution manometry

ABSTRACT

Background: The esophageal involvement in systemic sclerosis (SSc) causes impact in the morbidity and mortality. High resolution manometry assesses esophageal involvement. Our aim was to categorize esophageal motor disorder in patients with SSc by HRM.

Methods: We carried out an observational, descriptive and cross-sectional study. All patients underwent HRM as well as semi-structured interviews to assess frequency and severity of upper GI symptoms. Patients also completed the gastroesophageal reflux questionnaire (Carlsson-Dent).

Results: We included 19 patients with SSc, 1 with morphea, and 1 with scleroderma sine scleroderma. Dysphagia and heartburn were the most frequent symptoms (61% each). We found an abnormal HRM in 15 (71.4%) patients. We found no statistically significant association between clinical or demographic variables and an abnormal HRM, or between any upper GI symptom and HRM findings.

Conclusion: We observed a high prevalence of esophageal symptoms and of HRM abnormalities. However, there was no clear association between symptomatology and HRM findings. HRM does not seem to accurately predict upper GI symptomatology.

© 2017 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Falta de asociación de síntomas esofágicos con la manometría de alta resolución en pacientes con esclerosis sistémica

RESUMEN

Antecedentes: La afectación esofágica en la esclerosis sistémica causa impacto en la morbimortalidad. La manometría de alta resolución evalúa la afectación esofágica. Nuestro objetivo fue categorizar el trastorno motor esofágico en pacientes con esclerosis sistémica por HRM.

Métodos: Se realizó un estudio observacional, descriptivo y transversal. Todos los pacientes se sometieron a HRM, así como a entrevistas semiestructuradas para evaluar la frecuencia y la gravedad de los síntomas gastrointestinales. Los pacientes también completaron el cuestionario de reflujo gastroesofágico (Carlsson-Dent).

Resultados: Se incluyeron 19 pacientes con esclerosis sistémica, uno con morfea y uno con escleroderma sine escleroderma. La disfagia y la pirosis fueron los síntomas más frecuentes (un 61% cada uno). Encontramos una HRM anormal en 15 (71,4%) pacientes. No se halló ninguna asociación estadísticamente significativa entre las variables clínicas o demográficas y una HRM anormal, o entre cualquier síntoma GI superior y los hallazgos de HRM.

Conclusión: Se observó una alta prevalencia de síntomas esofágicos y de anomalías de la HRM. Sin embargo, no hubo asociación clara entre la sintomatología y los hallazgos de HRM. La HRM no parece predecir con precisión la sintomatología gastrointestinal.

© 2017 Elsevier España, S.L.U. y

Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Todos los derechos reservados.

Palabras clave:

Esclerosis sistémica

Enfermedad esofágica

Comorbilidad

Manometría de alta resolución

* Corresponding author.

E-mail address: drdavidvega@yahoo.com.mx (D. Vega-Morales).

Introduction

Systemic sclerosis (SSc) is an autoimmune disease of unknown cause characterized by microvasculopathy, fibroblast activation, and excessive production of collagen.¹

Involvement of the gastrointestinal (GI) tract in SSc is second in frequency only to the skin, and it is characterized by esophageal dysmotility in 75–90%, stomach involvement in 50%, small bowel involvement in 40–70%, colon involvement in 20–50%, and anorectal involvement in 50–70%.² The mortality rate attributable to GI involvement is 6–12%.^{3–7}

The great impact of esophageal involvement in the morbidity and mortality of SSc is related to its association with interstitial lung disease,⁸ weight loss and malnutrition, Barrett's esophagus^{9,10} and its progression to adenocarcinoma.¹¹ Around 18–40% of patients are asymptomatic despite the objective documentation of esophageal disease.¹⁰ Esophageal manometry is considered the method of choice for evaluation of esophageal motility in SSc patients, even when they are asymptomatic.

A new technique called high resolution manometry (HRM) in which catheters with 36 pressure sensors separated by 1 cm are used to measure intraesophageal pressure from the hypopharynx to the stomach, was introduced recently. The result is a color picture of the topography of esophageal pressure, where the duration, amplitude and velocity of esophageal contractions (including the function of the upper and lower esophageal sphincter) are plotted.¹² Traditionally, manometric findings were reported as rated by Spechler and Castell.¹³ From 2008 onwards (and with the introduction of the HRM) a new classification (The Chicago classification) was described, and is currently the most widely used classification.^{14,15} The aim of this study was to categorize esophageal motor disorder in patients with SSc by HRM and to describe its association with upper GI symptomatology.

Materials and methods

Setting and population

This is an observational, descriptive and cross-sectional study, carried out between May and August 2013 in a Tertiary-care University Hospital. This study was approved by the ethics committee of our Institution. We selected patients >18 years old with SSc according to the American College Classification 1980 with or without esophageal symptoms who accepted to enter to the study with a signed informed consent. Also, we included only two patients other than SSc, one with morphea and other with scleroderma *sine scleroderma*, both of them with esophageal symptoms.

We evaluated clinical and demographics variables including: age, gender, body mass index (BMI), SSc classification, auto-antibodies, previously use of nonsteroidal anti-inflammatory drug (NSAID), calcium channel blockers (CCB) and proton pump inhibitors (PPIs). We asked about esophageal symptoms using a semi-structured interview and recorded the frequency of: dysphagia, heartburn, regurgitation, cough, chest pain, nausea, vomiting. We also evaluated skin thickening, gastro esophageal reflux symptoms, and dysphagia symptoms.

Modified Rodnan skin score (mRSS)

The mRSS is a validated measure of skin thickening in SSc. In the mRSS, skin thickening is assessed at 17 body sites by palpation and rated on a scale with values of 0 (normal), 1 (mild), 2 (moderate) or 3 (severe skin thickening). The total skin score is the sum of the

individual skin assessments in the 17 body areas, with a possible range of 0–51; higher scores indicate more severe skin thickening.

Carlsson–Dent questionnaire

We applied a gastroesophageal reflux questionnaire (Carlsson–Dent) to all patients, which has been used in Spanish-speaking Mexican patients previously.¹⁶ It is a self-administered questionnaire that focuses on the nature of the sensations experienced by the patient as well as provoking, exacerbating and relieving factors. Scores range from –7 to 20. Scores of –7 to –1 indicate 'absent' reflux symptoms, 0–5 'mild', 6–11 'moderate' and >11 'severe' reflux symptoms.

Dysphagia

We classified dysphagia in four stages according to patient self-report: no dysphagia, dysphagia to liquid food, dysphagia to normal solids, dysphagia to soft solids and inability to swallow.

High resolution manometry (HRM)

HRM was done by a certified gastroenterologist (GBT) with experience using HRM. Seven days prior to HRM, we withheld the following drugs: prokinetics, narcotics, anticholinergics, antiemetics, and anti-inflammatory drugs. We asked the patient to fast the night before the procedure. The day of the study the patient was placed supine. Subsequently, topical anesthetic is applied in nostril. The manometry catheter was placed in a site that allowed to identify areas of both sphincters, placing about 5 sensors in the stomach and finally the probe was attached to the back of the nose. After a stabilization period of 5 min, 10 consecutive shots of 5 ml of water were administered every 30 s.¹⁷ HRM results were reported according to the Chicago classification.^{14–18} Patients with normal EGJ pressure, normal EGJ relaxation, normal PFV, and a DCI <5000 mm Hg s cm were reported as normal or abnormal if the gastroenterologist reported one of the following based in manometric parameters: Peristaltic dysfunction; aperistalsis, hypertensive peristalsis; rapidly propagated pressurization; abnormal LES tone (end expiratory); achalasia or functional obstruction.

Statistical analysis

Continuous variables with normal distribution were expressed with mean and standard deviation. Continuous variables without normal distribution were expressed with median and interquartile ranges. We categorized HRM results in two groups: Normal or abnormal HRM (any alteration), then, we used 2 × 2 contingency tables. In addition, chi-square or Fisher exact tests were used according to their distribution to assess whether there was an association between each variable and the HRM results. A value of $p < 0.05$ was considered statistically significant. All statistical analyses were performed using the SPSS version 20.0 statistical software package. This work has been assessed and approved by the local IRB with registration: RE13-006.

Results

We included 21 patients, 19 with SSc, 1 with morphea, and 1 with scleroderma *sine scleroderma*. Seventeen patients (80.9%) had less than three years of being diagnosed. Most patients were female (95.2%) with mean age of 44.9 (SD 14) years, a mean weight of 61.9 kg (SD 14.4) and height of 1.57 (SD 0.8) m; the other clinical and demographic variables are in Table 1. We found 17 (80.9%) patients with limited SSc. The mean mRSS for all patients was 9.7 (SD 7.4). Raynaud's phenomenon was reported in 18 (85.7%) patients.

Table 1
Clinical and demographic variables compared with HRM results.

Variable	Total (%) n = 21	HRM normal, n (%) n = 6	HRM abnormal, n (%) n = 15	p
Age, mean (SD) years	44 (14)	41.2 (10.2)	44.6 (14.3)	0.63
Female gender, n (%)	20 (95.2)	6 (100)	14 (93.3)	0.71
BMI				0.55
Normal, n (%)	7 (33.3)	1 (16.6)	6 (40)	
Underweight, n (%)	5 (23.8)	1 (16.6)	4 (26.6)	
Overweight, n (%)	5 (23.8)	2 (33.3)	3 (20)	
Obesity, n (%)	4 (19)	2 (33.3)	2 (13.3)	
SSc classification and variants				0.94
Limited, n (%)	17 (80.9)	4 (66.6)	13 (86.6)	
Diffuse, n (%)	2 (9.5)	0 (0)	2 (13.3)	
Scleroderma sine scleroderma, n (%)	1 (4.8)	1 (16.6)	0 (0)	
Morphea, n (%)	1 (4.8)	1 (16.6)	0 (0)	
mRSS ^a				0.39
Mild <20, n (%)	5 (23.8)	5 (83.3)	12 (80)	
Moderate ≥20, n (%)	0 (0)	0 (0)	3 (20)	
Raynaud phenomenon, n (%)	18 (85.7)	4 (66.6)	14 (93.3)	0.18
Antibodies				0.48
Antinuclear antibodies, n (%)	15 (75)	4 (66.6)	11 (73.3)	
Anti-Scl70, n (%)	5 (23.8)	1 (16.6)	4 (26.6)	0.51
Anti-centromere, n (%)	5 (23.8)	0 (0)	5 (33.3)	0.15
Drugs				
NSAID, n (%)	2 (9.5)	1 (16.6)	1 (6.6)	0.50
CCB, n (%)	18 (85.7)	4 (66.6)	14 (93.3)	0.18
PPI, n (%)	20 (95.2)	5 (83.3)	15 (100)	0.28

SSc, systemic sclerosis; SD, standard deviation; BMI, body mass index; mRSS, modified Rodnan skin score; NSAID, nonsteroidal anti-inflammatory drug; CCB, calcium channel blockers; PPI, proton pump inhibitors; HRM, high resolution manometry.

^a 20 patients.

We found a normal HRM in 6 (28.5%) patients and an abnormal HRM in 15 (71.4%) patients. Patients with an abnormal HRM were: 1 (6.6%) patient with distal esophageal spasm, 5 (33.3%) patients with absent peristalsis, 4 (26.6%) patients with weak peristalsis with small peristaltic defects, and 3 (20%) patients with frequent failed peristalsis. Only 2 (13.3%) patients in whom an abnormal HRM was found could not be classified.

The association between upper GI symptoms and HRM results is shown in Table 2. Dysphagia and heartburn were the most frequent symptoms reported by the patients, but in general, symptom frequency did not vary between groups with or without HRM abnormalities. Only regurgitation was found to be more frequent in patients with a normal HRM. Additionally, neither the Carlsson–Dent questionnaire nor dysphagia severity was different between groups. Two patients with limited SSc who were asymptomatic (one patient with absent peristalsis and the other with weak peristalsis with small peristaltic defects) showed an abnormal HRM. The two variant SSc patients (scleroderma sine scleroderma and morphea) had a normal HRM.

Discussion

In this cohort of SSc patients, an abnormal HRM was found in 71.4%. Dysphagia and heartburn were the most common esophageal symptoms reported, which is similar to other published series.^{8–10} We did not find any association between clinical-demographic variables and the outcome of the HRM, or between

Table 2
Association between upper GI symptoms and HRM results.

Variable	Total (%) n = 21	HRM normal, n (%) n = 6	HRM abnormal, n (%) n = 15	p
<i>Esophageal symptoms, n (%)</i>				
Dysphagia	13 (61.9)	4 (66.6)	9 (60)	0.59
Heartburn	13 (61.9)	3 (50)	10 (66.6)	0.41
Regurgitation	9 (42.9)	5 (83.3)	4 (26.6)	0.02
Cough	10 (47.6)	3 (50)	7 (46.6)	0.63
Chest pain	3 (14.3)	2 (33.3)	1 (6.6)	0.18
Nausea	4 (19)	2 (33.3)	2 (13.3)	0.31
Vomiting	1 (4.8)	0 (0)	1 (6.6)	0.71
CDQ, mean (SD)	6.04 (4.4)			0.59
0–3 score, n (%)	8 (38)	3 (50)	5 (33.3)	
4–15 score, n (%)	13 (61.9)	3 (50)	10 (66.6)	
<i>Dysphagia classification, n (%)</i>				
No dysphagia	9 (42.8)	4 (66.6)	5 (33.3)	0.37
Dysphagia to normal solids ^a	7 (53.8)	1 (16.6)	5 (33.3)	
Dysphagia to soft solids ^a	6 (46.1)	1 (16.6)	5 (33.3)	
4–15 score, n (%)	7 (33.3)			

CDQ, Carlsson–Dent questionnaire; HRM, high resolution manometry.

^a 20 patients.

upper GI symptoms and HRM findings, except for regurgitation, which was found to be more frequent in patients with a normal HRM.

There had been a previous study assessing the clinical features of Mexican scleroderma patients; Santos-Navarro et al.¹⁹ studied 60 patients and found hypotensive lower esophageal sphincter (LES) in 95%. Aperistalsis (41%), slight hypomotility (30%), and severe hypomotility (27%) with different gastric manifestations as: early satiety 45%, abdominal pain 35%, nausea 20% and vomiting 10%. In contrast with our study they did not intent to correlate the clinical findings with manometry ones. Also they performed standard manometry versus high resolution in our patients. Even tough, they found a high prevalence of manometry alterations, maybe explained by age differences between cohorts, and the established disease by ten years of more.

This is not the first study to find a lack of an association between esophageal dysmotility evaluated by HRM and upper GI symptomatology in patients with SSc. Roman et al. studied HRM findings in 51 patients with SSc, and found that 67.3% had HRM abnormalities (most commonly hypotensive esophagogastric junction). However, up to 87% of patients had esophageal symptoms that were not predictive of HRM alterations.²⁰ Later, Tang et al. associated HRM findings with phenotypic and GI symptoms in 28 patients with SSc, and could not find a clear association between dysphagia and HRM findings.²¹ Recently, Raja et al. reported the finding of a study on 31 patients with SSc who underwent HRM.²² They found that upper GI symptoms were absent in the majority of their patients, even when they had severe esophageal involvement according to HRM findings. The same basic results were reported in another recent study involving 79 patients with SSc.²³

It has been known for some time that the severity of upper GI symptoms does not always correlate with objective measures of esophageal dysmotility, and this may include HRM. In a retrospective study of over 250 patients who underwent HRM due to upper GI symptoms, these were not found to be related to abnormal motor function defined by HRM during liquid, viscous or solid bolus swallows in the upright position.²⁴ The discordance that we observed in our study might not be limited to patients with SSc. Other studies on populations with systemic diseases that usually involve the esophagus, such as

Chagas disease, have similarly found a lack of an association between HRM findings and upper GI symptomatology.²⁵ Additionally, in our study, 95.2% of patients at the time of evaluation were treated with proton pump inhibitors (PPIs). The lack of association between the symptoms and the results of HRM may be also partly explained by the high percentage of patients using PPIs at the time of evaluation, or even the use of other non-prescription medications for heartburn that could mask the symptoms evaluated. This limitation was also seen in other study.²¹

On the other hand, there are certain features of SSc that have been more consistently associated with HRM alterations. Patients with SSc and Raynaud phenomenon have been found to have lower amplitude of distal esophageal contractions²¹ as well as with more hypotensive lower esophageal sphincter²² compared to those without. Degree of skin involvement has also been positively correlated with esophageal dysmotility according to HRM as well as with more severe dysphagia.^{21,23} The latter were not found in our cohort. The presence of pulmonary fibrosis in SSc patients was also found to be associated with more absent contractility in HRM as well as with more symptoms of gastroesophageal reflux.^{22,23} At least one study found that alterations in HRM were correlated to presence of Scl70 and absence of anti-centromere antibodies,²⁰ but these findings were not replicated in another recent study.²³ In our study we did not assess lung function, and neither the severity of skin involvement or presence of Raynaud phenomenon was significantly associated with HRM abnormalities, although there was a trend toward more alterations in patients with Raynaud phenomenon.

The patients with morphea and scleroderma sine scleroderma we included both had a normal HRM. Recently, Arif et al. evaluated SSc and morphea patients with upper gastrointestinal endoscopy, esophageal manometry and 24-h pH monitoring, and found that of the 31 patients with morphea, none had manometric findings, although only four patients had symptoms. The authors concluded that in morphea, an assessment of GI manifestations is not necessary, unlike SSc.²⁶ We also observed two patients with SSc without esophageal symptoms but with an abnormal HRM. Previously, Thonhofer et al. conducted a retrospective study, where they evaluated patients with SSc and Mixed Connective Tissue Disease (MCTD) without GI symptoms. The patients underwent a baseline evaluation and follow-up at three to six months. In all thirteen SSc patients, significant pathology of the upper GI-tract was found. In patients with esophageal abnormalities, starting treatment led to favorable results, which was confirmed in the follow-up study. The authors suggest that the GI evaluation must be performed early in patients diagnosed with SSc, even if they do not report typical symptoms,²⁷ an opinion that we share considering our results.

We consider that the strengths of the study are: a population with a relatively early diagnosis of SSc, the use of HRM and the Chicago classification. The limitations include: cross-sectional study design, small cohort of patients, heterogeneity in the treatment of patients, lack of description of other comorbidities that could affect the outcome of the HRM, as well as lack of further studies to complement the manometry result, such as pH monitoring or endoscopy.

In conclusion, we found a high prevalence of esophageal symptoms but a lack of association between these and the presence of an abnormal HRM, which is in accordance to other published studies.^{19–22} This suggests that it is important to perform a systematic approach to GI symptomatology in SSc patients at diagnosis irrespective of objective procedures of motility evaluation. This will identify early GI abnormalities, help alleviate symptoms and thereby lessen the impact on morbidity and mortality generated by this condition.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Funding sources

None.

Authors' contribution

Arana-Guajardo AC: study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; obtained funding; administrative, technical, or material support.

Barrera-Torres G: acquisition of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content.

Villarreal-Alarcón MA: study concept and design; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; study supervision.

Vega-Morales D: study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content; statistical analysis; study supervision.

Esquivel-Valerio JA: analysis and interpretation of data; drafting of the manuscript; critical revision of the manuscript for important intellectual content.

Conflict of interest

None declared.

References

1. Coral-Alvarado P, Pardo AL, Castano-Rodriguez N, Rojas-Villarraga A, Anaya JM. Systemic sclerosis: a world wide global analysis. *Clin Rheumatol.* 2009;28:757–65.
2. Sjogren RW. Gastrointestinal motility disorders in scleroderma. *Arthritis Rheum.* 1994;37:1265–82.
3. Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). *Arthritis Rheum.* 1991;34:403–13.
4. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, et al. Mortality in systemic sclerosis (scleroderma). *Q J Med.* 1992;82:139–48.
5. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. *Ann Rheum Dis.* 1998;57:682–6.
6. Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. *J Rheumatol.* 2001;28:2454–9.
7. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, Goulet JR, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. *Medicine (Baltimore).* 2002;81:154–67.
8. Christmann RB, Wells AU, Capelozzi VL, Silver RM. Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. *Semin Arthritis Rheum.* 2010;40:241–9.

9. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. *Rheumatology (Oxford)*. 2009;48 Suppl. 3:iii36–9.
10. Ebert EC. Esophageal disease in scleroderma. *J Clin Gastroenterol*. 2006;40:769–75.
11. Wipff J, Coriat R, Masciocchi M, Caramaschi P, Derk CT, Hachulla E, et al. Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR scleroderma trials and research prospective follow-up study. *Rheumatology (Oxford)*. 2011;50:1440–4.
12. Abreu-Y Abreu ATGSC, Villanueva Sáenz E, Valdovinos Díaz MA. Differences between Chicago and traditional classifications in the diagnosis of esophageal motor disorders with high-resolution manometry and topography of esophageal pressure. *Rev Gastroenterol Mex*. 2010;75:412–20.
13. Spechler SJ, Castell DO. Classification of oesophageal motility abnormalities. *Gut*. 2001;49:145–51.
14. Pandolfino JE, Ghosh SK, Rice J, Clarke JO, Kwiatek MA, Kahrilas PJ. Classifying esophageal motility by pressure topography characteristics: a study of 400 patients and 75 controls. *Am J Gastroenterol*. 2008;103:27–37.
15. Bredenoord AJ, Fox M, Kahrilas PJ, Pandolfino JE, Schwizer W, Smout AJ, et al. Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. *Neurogastroenterol Motil*. 2012;24 Suppl. 1:57–65.
16. Gómez-Escudero O, Remes-Troche JM, Ruíz JC, Peláez-Luna M, Schmulson MJ, Valdovinos Díaz MA. Diagnostic usefulness of the Carlsson–Dent questionnaire in gastroesophageal reflux disease (GERD). *Rev Gastroenterol Mex*. 2004;69:16–23.
17. Committee AT, Wang A, Pleskow DK, Banerjee S, Barth BA, Bhat YM, et al. Esophageal function testing. *Gastrointest Endosc*. 2012;76:231–43.
18. Kahrilas PJ, Ghosh SK, Pandolfino JE. Esophageal motility disorders in terms of pressure topography: the Chicago classification. *J Clin Gastroenterol*. 2008;42:627–35.
19. Santos-Navarro RR, Mendez-del-Monte R, Del Real-Calzada C, Vera-Lastra OL. Clinical, endoscopic and manometric findings in the gastroesophageal tract of patients with systemic sclerosis. *Rev Med Inst Mex Seguro Soc*. 2007;46:503–10.
20. Roman S, Hot A, Fabien N, Cordier JF, Miossec P, Ninet J, et al. Esophageal dysmotility associated with systemic sclerosis: a high-resolution manometry study. *Dis Esophagus*. 2011;24:299–304.
21. Tang DM, Pathikonda M, Harrison M, Fisher RS, Friedenberg FK, Parkman HP. Symptoms and esophageal motility based on phenotypic findings of scleroderma. *Dis Esophagus*. 2013;26:197–203.
22. Raja J, Ng CT, Sujau I, Chin KF, Sockalingam S. High-resolution oesophageal manometry and 24-hour impedance-ph study in systemic sclerosis patients: association with clinical features, symptoms and severity. *Clin Exp Rheumatol*. 2016;34 Suppl. 100:115–21.
23. Kimmel JN, Carlson DA, Hinchcliff M, Carns MA, Aren KA, Lee J, et al. The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters. *Neurogastroenterol Motil*. 2016;28:1157–65.
24. Xiao Y, Kahrilas PJ, Nicodeme F, Lin Z, Roman S, Pandolfino JE. Lack of correlation between hrm metrics and symptoms during the manometric protocol. *Am J Gastroenterol*. 2014;109:521–6.
25. Sanchez-Montalva A, Moris M, Mego M, Salvador F, Accarino A, Ramirez K, et al. High resolution esophageal manometry in patients with Chagas disease: a cross-sectional evaluation. *PLoS Negl Trop*. 2016;10:e0004416.
26. Arif T, Masood Q, Singh J, Hassan I. Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and ph metric features: a prospective comparative hospital based study. *BMC Gastroenterol*. 2015;15:24.
27. Thonhofer R, Siegel C, Trummer M, Graninger W. Early endoscopy in systemic sclerosis without gastrointestinal symptoms. *Rheumatol Int*. 2012;32:165–8.